Geron Corporation (GERN)

Market Cap	1.05B -38.2%
Revenue (ttm)	183.88M +138.8%
Net Income	-85.78M
EPS	-0.13
Shares Out	638.36M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	19,257,426
Open	1.720
Previous Close	1.720
Day's Range	1.540 - 1.740
52-Week Range	1.040 - 2.010
Beta	0.62
Analysts	Buy
Price Target	2.90 (+75.76%)
Earnings Date	Feb 25, 2026

About GERN

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 30, 1996
• Employees: 229
• Stock Exchange: NASDAQ
• Ticker Symbol: GERN
• Website: https://www.geron.com

Financial Performance

In 2025, Geron's revenue was $183.88 million, an increase of 138.83% compared to the previous year's $76.99 million. Losses were -$85.78 million, -50.86% less than in 2024.

Analyst Summary

According to 6 analysts, the average rating for GERN stock is "Buy." The 12-month stock price target is $2.9, which is an increase of 75.76% from the latest price.

Price Target

$2.9

(75.76% upside)

Analyst Consensus: Buy